Alto Neuroscience (NYSE:ANRO) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Alto Neuroscience from “hold” to “sell,” adding a bearish view despite the broader analyst consensus remaining “Moderate Buy” with a $37.25 target price.
• Alto Neuroscience shares opened at $32.01, up 1%, and have climbed substantially from a 52-week low of $3.59; the stock’s 52-week high is $37.48.
• The clinical-stage biotechnology company reported a quarterly loss of $0.65 per share, beating expectations for a $0.73 loss, while analysts project a full-year loss of $2.68 per share.

Alto Neuroscience (NYSE:ANRO - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other equities analysts also recently commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Zacks Research upgraded shares of Alto Neuroscience from a "strong sell" rating to a "hold" rating in a report on Thursday, August 20th. HC Wainwright lifted their price objective on shares of Alto Neuroscience from $50.00 to $55.00 and gave the stock a "buy" rating in a research report on Monday, August 17th. Wolfe Research started coverage on shares of Alto Neuroscience in a research note on Friday, May 22nd. They set an "outperform" rating for the company. Finally, BTIG Research boosted their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a "buy" rating in a research note on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Alto Neuroscience presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.25.

Alto Neuroscience Stock Up 1.0%

NYSE ANRO opened at $32.01 on Friday. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 52 week low of $3.59 and a 52 week high of $37.48. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -13.23 and a beta of 1.13. The company has a fifty day moving average of $30.68 and a two-hundred day moving average of $25.33.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.08. On average, analysts predict that Alto Neuroscience will post -2.68 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

A number of large investors have recently added to or reduced their stakes in ANRO. GK Wealth Management LLC acquired a new position in shares of Alto Neuroscience during the second quarter valued at approximately $226,000. California State Teachers Retirement System acquired a new stake in shares of Alto Neuroscience in the second quarter worth approximately $251,000. Balyasny Asset Management L.P. purchased a new stake in shares of Alto Neuroscience during the fourth quarter worth approximately $198,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Alto Neuroscience during the fourth quarter worth approximately $221,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Alto Neuroscience in the 4th quarter valued at $304,000.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.